Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 19, 2009

Sopherion Pockets $55M to Support Late-Stage Trial with Anticancer Agent

  • Sopherion Therapeutics secured $55 million to complete Phase III development of Myocet in breast cancer. The series C financing was led by Zoticon Bioventures.

    Myocet is a liposomal formulation of doxorubicin, reportedly designed to reduce the risk of cardiotoxicity. It is being studied in combination with trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first-line therapy of patients with metastatic breast cancer.

    In January 2008, Zoticon in-licensed Myocet and provided $20 million. Subsequently, it led an additional $35 million funding during 2008. Additional investors in this second tranche of funding include TL Ventures, New Leaf Venture Partners/Sprout Group, ProQuest Investments, Canaan Partners, Devon Park Bioventures, Commerce Bank, and NewSpring Capital.

    Sopherion originally gained an exclusive license in 2004 from Zeneus Pharma, which is now Cephalon, to commercialize Myocet in North America.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »